[Honvan-high-dose therapy of prostatic carcinoma with metastases: early complications and value of prophylaxis against thrombosis].
Since 1972 in the Urology Department at Darmstadt Hospital the Honvan-high-dose-therapy of 130 patients with metastatic prostatic carcinoma has been carried out under standardizing condition. The analysis shows that there is no significant difference between the patients with prophylaxis against thrombosis (Macrodex and Dihydergot-Heparin) and without prophylaxis. The patients with anti-thrombotic prophylaxis demonstrated significantly higher incidence of reversible elevation of transaminases. The effect of Heparin is probably responsible for this.
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004054:Diethylstilbestrol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000150:complications / Q000188:drug therapy*; D012189:Retrospective Studies; D013923:Thromboembolism / Q000517:prevention & control*
D000970:Antineoplastic Agents; D004054:Diethylstilbestrol; C004955:fosfestrol
Honvan-Stoss-Therapie bei metastasierendem Prostatakarzinom: Frühkomplikationen und Wertigkeit einer thromboembolischen Prophylaxe.